Literature DB >> 19337710

[Nephrogenic systemic fibrosis].

Stefan Becker1, Oliver Witzke, Andreas Kribben.   

Abstract

Nephrogenic systemic fibrosis is a highly debilitating and emotionally depressing disorder. So far, it has exclusively occurred in patients suffering from acute or chronic renal failure. Most patients had been exposed to gadolinium- based contrast agents. Early symptoms include pain, swelling and pruritus, predominantly of the extremities. Fibrosis of the skin and other organs develops in the further course of the disease. The diagnosis is made based on the synopsis of medical history, clinical and dermatohistological findings. To avoid the application of gadolinium-based contrast agents in patients with highly impaired renal function is the best measure to prevent the disease. An effective therapy has not yet been established. Possible therapies, which have been successful in individual cases, comprise, among others, a quick restoration of renal function, physiotherapy, and extracorporeal photopheresis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337710     DOI: 10.1007/s00063-009-1033-7

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  39 in total

1.  Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability.

Authors:  J Behra-Miellet; B Gressier; C Brunet; T Dine; M Luyckx; M Cazin; J C Cazin
Journal:  Methods Find Exp Clin Pharmacol       Date:  1996-09

Review 2.  Nephrogenic systemic fibrosis: an update.

Authors:  Shawn E Cowper; Philip J Boyer
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

3.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.

Authors:  Christopher Heeschen; Alexandra Aicher; Ralf Lehmann; Stephan Fichtlscherer; Mariuca Vasa; Carmen Urbich; Christiane Mildner-Rihm; Hans Martin; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

4.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; James Goya Heaf; Henrik S Thomsen
Journal:  Nephrol Dial Transplant       Date:  2007-05-04       Impact factor: 5.992

5.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Authors:  Tara Anne Collidge; Peter Campbell Thomson; Patrick Barry Mark; James Phillip Traynor; Alan George Jardine; Scott Thomas William Morris; Keith Simpson; Giles Hannibal Roditi
Journal:  Radiology       Date:  2007-08-17       Impact factor: 11.105

6.  Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.

Authors:  Heather Richmond; Jeffrey Zwerner; Youn Kim; David Fiorentino
Journal:  Arch Dermatol       Date:  2007-08

7.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.

Authors:  Aneet Deo; Mitchell Fogel; Shawn E Cowper
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

8.  Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.

Authors:  Preethi Yerram; Georges Saab; Poorna R Karuparthi; Melvin R Hayden; Ramesh Khanna
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

9.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

Authors:  Julian M Mackay-Wiggan; David J Cohen; Mark A Hardy; Elizabeth H Knobler; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

Review 10.  [Nephrogenic systemic fibrosis--a new interdisciplinary challenge].

Authors:  O Witzke; U Hillen; J Barkhausen; A Daul; A Kribben
Journal:  Dtsch Med Wochenschr       Date:  2007-12       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.